This cohort study compares trends in initiation of treatment with glucagonlike peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors, and dipeptidyl peptidase-4 inhibitors by older adults with type 2 diabetes insured by Medicare Advantage vs commercial health plans. Here, SLC5A2 is linked to type 2 diabetes mellitus.